Development of novel therapies for Huntington's disease: hope and challenge

被引：12
|
作者：
Qin, ZH [1 ]
Wang, J
Gu, ZL
机构：
[1] Soochow Univ, Sch Med, Dept Pharmacol, Suzhou 215007, Peoples R China
[2] Massachusetts Gen Hosp, Lab Cellular Neurobiol, Charlestown, MA 02129 USA
[3] Harvard Univ, Sch Med, Charlestown, MA 02129 USA
[4] Massachusetts Gen Hosp, Mol Neurogenet Unit, Ctr Human Genet Res, Charlestown, MA 02129 USA
来源：
ACTA PHARMACOLOGICA SINICA | 2005年 / 26卷 / 02期
关键词：
Huntington disease; huntingtin; aggregates; caspases; nerve growth factors; cell transplantation; coenzyme Q10;
D O I：
10.1111/j.1745-7254.2005.00520.x
中图分类号：
O6 [化学];
学科分类号：
0703 ;
摘要：
Huntington's disease (HD) is an autosomal dominant neurological disease. It is a fatal neurological disorder affecting 5-10 out of 10 000 people. While there are intensive research efforts focusing on uncovering molecular mechanisms of the pathogenesis of HID, a number of studies have begun to look for effective therapies for HD. There is a large body of encouraging news on novel therapeutic developments. The present paper reviews drugs used for symptomatic treatment of HD and experimental therapies targeting HD molecular pathology.
引用
收藏
页码：129 / 142
页数：14
相关论文
共 50 条
12345